Charles Schwab Investment Management Inc Applied Therapeutics Inc. Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 24,504 shares of APLT stock, worth $114,433. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,504

Previous 24,504 -0.0%

Holding current value

$114,433

Previous $82,000 102.44%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$0.77 - $1.8 $18,868 - $44,107	24,504 New	24,504 $31,000
Q2 2022 Aug 15, 2022	SELL	$0.76 - $2.64 $29,615 - $102,875	-38,968 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.48 - $6.22 $9,044 - $38,010	-6,111 Reduced 13.56%	38,968 $83,000
Q4 2021 Feb 11, 2022	BUY	$8.77 - $18.29 $15,286 - $31,879	1,743 Added 4.02%	45,079 $404,000
Q3 2021 Nov 16, 2021	SELL	$13.54 - $22.06 $4,292 - $6,993	-317 Reduced 0.73%	43,336 $720,000

Q2 2021 Aug 16, 2021	BUY	$14.05 - $25.04 $63,323 - $112,855	4,507 Added 11.51%	43,653 $908,000
Q1 2021 May 17, 2021	BUY	$16.57 - $28.65 $83,545 - $144,453	5,042 Added 14.78%	39,146 $735,000
Q4 2020 Feb 16, 2021	SELL	$15.44 - $24.23 $1,405 - $2,204	-91 Reduced 0.27%	34,104 $751,000
Q3 2020 Nov 13, 2020	BUY	$19.43 - $35.36 $42,357 - $77,084	2,180 Added 6.81%	34,195 $710,000
Q2 2020 Aug 14, 2020	BUY	$29.41 - $51.23 $339,067 - $590,630	11,529 Added 56.28%	32,015 $1.16 Million
Q1 2020 May 15, 2020	BUY	$19.54 - $55.47 $133,751 - $379,692	6,845 Added 50.18%	20,486 $670,000
Q4 2019 Feb 07, 2020	BUY	$10.16 - $28.14 $138,592 - $383,857	13,641 New	13,641 $373,000

Others Institutions Holding APLT

# of Institutions

100

Shares Held

94M

Call Options Held

5.83M

Put Options Held

231K

View Full List

About Applied Therapeutics Inc.

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $224M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

More about APLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Applied Therapeutics Inc. Transaction History